Morgan Stanley has initiated coverage on West Pharmaceutical Services Inc (WST), assigning the company an Equal-Weight rating. This marks the firm’s first evaluation of West Pharmaceutical's investment potential based on its analysis of the business and industry dynamics.
West Pharmaceutical Services, headquartered in Exton, Pennsylvania, specializes in the manufacture and marketing of pharmaceuticals, biologics, vaccines, and consumer healthcare products. The company operates in two segments: Proprietary Products, which includes elastomers and drug delivery devices, and Contract-Manufactured Products, focused on the design and assembly of complex devices for various medical applications.
As of December 1, 2025, West Pharmaceutical's stock trades at $281.36, with a market capitalization of $19.5 billion. The company reports a P/E ratio of 39.66 and an EPS of 6.75. Investors should note that upcoming earnings are scheduled for July 22, 2026, with an estimated EPS of $1.97 and revenue of $823.8 million.
Analyst ratings like this one provide insights based on research and financial modeling. However, they should be considered alongside other factors such as company fundamentals and market trends, rather than being the sole basis for investment decisions. Ratings can evolve as new information becomes available, and differing opinions among analysts are common.